Mirabilis Health has earned its reputation by blending innovation with integrity. As the first prescribing site for TSND‑201 in PTSD trials and enrolled more than half of study participants in 2025’s IMPACT‑1 trial for severe, treatment-resistant trauma, they’ve demonstrated clinical leadership and scientific trust. Their compassionate protocols are providing participants with new hope—and inspiration for future research pathways. Learn about their research at https://mirabilishealth.com/